CD8A and neoplasm: Results from the tumor re-challenge experiment demonstrated that the Nefmut/E6 plus Nefmut/E7 vaccine conferred a potent, long lasting (at least up to 38 weeks after the last immunization), and effective CD8+ T cell immunity, which acted against the tumors re-implanted 19 weeks after the last immunization.